CTLA4 and melanoma: Since anti-CTLA-4 (ipilimumab) was approved for melanoma treatment, which promotes T-cell activation by blocking the interaction of CTLA4 with CD80 and CD86 [55], the clinical successes achieved by blocking CTLA-4 and PD-1 have inspired further exploration of the potential of ICB therapies.